Press releases (embargo: 6 May, 16:45 CEST)
J. Hicks, USAGenome breakthrough allows scientists to identify and profile tumor cells from very small samplesResearchers have developed a powerful new technique for analyzing the genome of single tumor cells. The breakthrough allows them to study in fine detail the biology of how tumors develop.
S. Loi, BEEstrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapiesAn international team of researchers has discovered molecular evidence that may explain why some women with HER2 over-expressing breast cancer do not respond to drugs designed to target this important molecule.
B. Haine-Kains, USASimple gene test identifies clinically important sub-types of breast cancerA simple genetic test that uses just three genes is among the most effective means of classifying breast cancer into sub-types.
A. Giordano, USASurvival in metastatic breast cancer directly linked to circulating tumor cellsA new study of metastatic breast cancer shows that the number of circulating tumor cells patients have in their blood directly correlates with the length of their survival.
The full conference program is available at http://www.esmo.org/events/breast-2010-impakt/program.html
Press conference
Thursday, 06/05 at 12:00-13:00 (CEST)
Hosts:Dr Martine Piccart, Head of Chemotherapy Unit, Jules Bordet Institute in Brussels, IMPAKT Co-FounderDr Angelo Di Leo, Head of Medical Oncology Unit, Department of Oncology, Hospital of Prato, Italy, IMPAKT2010 Co-ChairDr Christos Sotiriou, Head of Functional Genomics & Translational Research Unit, Jules Bordet Institute in Brussels, IMPAKT2010 Co-Chair
Topics:
- The impact of methodology in biomarkers research and validation
- Translational research impact on the next decade
- Impact of neo-adjuvant trial results in the future treatment practice